Ontology highlight
ABSTRACT:
SUBMITTER: Lowenberg B
PROVIDER: S-EPMC4186639 | biostudies-literature | 2011 Dec
REPOSITORIES: biostudies-literature
Löwenberg Bob B Muus Petra P Ossenkoppele Gert G Rousselot Philippe P Cahn Jean-Yves JY Ifrah Norbert N Martinelli Giovanni G Amadori Sergio S Berman Ellin E Sonneveld Pieter P Jongen-Lavrencic Mojca M Rigaudeau Sophie S Stockman Paul P Goudie Alison A Faderl Stefan S Jabbour Elias E Kantarjian Hagop H
Blood 20111005 23
The primary objective of this 2-part phase 1/2 study was to determine the maximum-tolerated dose (MTD) of the potent and selective Aurora B kinase inhibitor barasertib (AZD1152) in patients with newly diagnosed or relapsed acute myeloid leukemia (AML). Part A determined the MTD of barasertib administered as a continuous 7-day infusion every 21 days. In part B, the efficacy of barasertib was evaluated at the MTD. In part A, 32 patients were treated with barasertib 50 mg (n = 3), 100 mg (n = 3), 2 ...[more]